In the present study, we performed a systematic analysis of IDH mutations in a large number of Chinese patients with NSCLC and preliminarily explored the role of IDH inhibitors in lung cancer cells through in vitro experiments. The gene discussed is IDH2; the disease is lung carcinoma.